Kedrion Biopharma has always been globally committed to providing wider, fairer access to plasma-derived therapies for the treatment of hemophilia and other coagulation disorders, also by supporting ethical, transparent and sustainable projects in disadvantaged countries. This will be confirmed once again on the World Haemophilia Day 2017, which is celebrated all over the world on April 17th.
In Italy, on April 10th a conference was organised in Rome by FedEmo (Federazione delle Associazioni Emofilici, Federation of Hemophilia Associations) in partnership with the AICE (Associazione Italiana Centri Emofilia, Italian Association of Hemophilia Centers) and sponsored by the Health Ministry. Patient associations, doctors and health authorities will take part in the event. Stefano Marroni, deputy Director of news programmes TG2, chaired a talk about “Hemophilic patients in A&E: the importance of triage".
In Milan, on 20th April, Fondazione Paracelso will be hosting the meeting “The medicine we like”, in partnership with AICE and FedEmo. Guests will include patient associations, doctors, companies, politicians and journalists, to discuss ability, disability and diseases, with a focus on Fondazione Paracelso’s “BarrieraZero” project for kids.
Both initiatives are supported by Kedrion and other industry companies.
On a European level, in 2017 Kedrion once again will be supporting the European Hemophilia Consortium (EHC), that will celebrate World Hemophilia Day with an event in Strasbourg, France, on 19th April, to discuss the guidelines issued by the European Directorate for Quality of Medicines and Healthcare (EDQM).
In Mexico City, on 16th April, a march will walk along one of the most important streets of the capital. The event is organised by the Hemophilia Federation of the Republic of México (FHRM), and Kedrion will take part in the initiative involving for the first time the biggest distributor in the Country for haemophilia (Fármacos Especializados) and alongside patient associations and leading haematologists of the country.
Besides, to celebrate this Day and Kedrion Biopharma’s sixth year in the United States, the company will be supporting 6 bleeding disorder patients from India, Kenya, Egypt and Romania through the non-profit program Save One Life.
Kedrion’s efforts for haemophilic patients’ communities across the world go far beyond the events of the XIII World Haemophilia Day. Among other things, in 2017 the company will be supporting again the World Federation of Haemophilia (WFH) and its humanitarian initiatives, aimed to fill the gaps in access to concentrate coagulation factors: such as WISH, a programme entered into with the Italian National Blood Centre (CNS) in 2015 for sending plasma-derived products from national plasma to disadvantaged countries; and the Global Alliance for Progress (GAP), launched in 2013 and already up and running in 26 countries.
